13Effect Monitoring and Insights from Vaccination program of Healthcare Workforce from a tertiary level hospital in India against SARS-CoV-2

Rajat Ujjainia[1,2#], Akansha Tyagi[3#], Viren Sardana[1,2#], Salwa Naushin[1,2], Nitin Bhatheja[1], Kartik Kumar[1], Joydeb Barman[1], Satyaratha Prakash[1], Rintu Kutum[1,2], Akash Bhaskar[1,2], Menka Loomba[3], Yukti Khanna[3], Chestha Walecha[3], Rizwan Ahmed[3], Ashutosh Yadav[4], Archana Bajaj[11], Gaurav Malik[11], Sahar Qureshi[10], Swati Waghdhare[4], Samreen Siddiqui[4], Kamal Krishan Trehan[11], Manju Mani[10], Rajiv Dang[9], Poonam Das[6], Pankaj Dougall[7], Monica Mahajan[8], Sandeep Buddhiraja[5] , Anurag Agrawal[1,2], Debasis Dash[1,2*], Sujeet Jha[4*], Shantanu Sengupta[1,2*]

[1]CSIR-Institute of Genomics and Integrative Biology, New Delhi
[2]Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh
[3]Department of Clinical Research Max Superspeciality Hospital, Saket, New Delhi
[4]Institute of Endocrinology, Diabetes, and Metabolism, New Delhi
[5]Department of Internal Medicine, Max Superspeciality Hospital, Saket, New Delhi
[6]Institute of Laboratory Medicine & Transfusion Services. Max Hospital, Saket, New Delhi
[7]Max Hospital, Saket, New Delhi
[8]Max Hospital Panchsheel, New Delhi
[9]Max Hospital, Gurgaon, New Delhi
[10]Max Smart Super Speciality Hospital, New Delhi
[11]Max Hospital Shalimar Bagh, New Delhi

[#] Co-First Authors with Equal Contribution

[*] Corresponding authors

Abstract

The Oxford-Astra Zeneca COVID 19 vaccine (AZD1222 or ChAdOx1) is locally manufactured as Covishield by Serum Institute, Pune, India. In a group of 307 healthcare workers administered Covishield, we report measured antibody response to SARS-CoV-2 directed against the spike protein (S-antigen) at days 0, 7, 14, 28 and 45, with second dose on day 28 for all except 20 subjects who did not receive a second dose. In 129 subjects (42%) who had already developed antibodies to SARS-CoV-2 at day 0 (before immunization), it was observed that antibody response was significantly higher at each time point, with the maximum increase seen between days 0 and 7. The antibody levels and neutralizing activity in these subjects had peaked by day 28 and the second dose did not lead to further increase. Data from 9 subjects who were seropositive at baseline and received only one dose was similar to those who received both doses. In contrast the baseline sero-negative group (n=178) started developing antibody response only after 14 days or later. Administration of the second dose was associated with further increase in antibody levels at day 45 compared to day 28, with marked increase in neutralizing activity. In baseline seronegative subjects, who did not take the vaccine at day 28 (n=11), the antibody levels increased by about 2.5 folds between days 28 and 45, with minimal change in the neutralizing antibodies. In general, vaccination was well tolerated, and there were no group specific differences in post-vaccination symptomatology. Our data suggests that ChAdOx1 is highly immunogenic, particularly so where previous SARS CoV2 antibody-response is established. In such subjects, a single dose may be sufficient but in absence of such determination, both doses are required.

Keywords:

Covid 19, Vaccine, Antibody Response, SARS-CoV-2, Immunity, Public Health

Introduction

As the covid pandemic swept global economies last year, tireless efforts to develop vaccines against SARS-CoV-2 were underway and a few vaccines have already been developed in record time to control the spread of SARS-CoV-2 infection worldwide. To protect at the earliest the vulnerable and exposed from acquiring the dreaded infection; frontline healthcare workers, sanitization staff, elderly with co-morbidities etc. was at high priority of governments around the world. India began its ambitious vaccination program from January 2021 after approval of two candidate vaccines; one being Covishield (AZD1222 technology acquired from co-development of Oxford University and AstraZeneca, by Serum Institute of India, Pune) and the other being Covaxin (Bharat Biotech developed vaccine using Vero cell lines in collaboration with ICMR, India) after an emergency restricted use approval by the Central Drugs Standard Control Organisation (CDSCO).[1] Both vaccines had peer reviewed studies published demonstrating the immunogenicity after extensive clinical trials,[2-4] though Covaxin was to undergo phase III trials, it was given an approval for restricted use under emergency situation in a clinical trial mode.

With the introduction and approval of vaccines, it became imperative to understand the immunogenicity and efficacy in antibody development. In a study carried out in regard to Pfizer and Moderna vaccine, researchers observed a significant difference in antibody response and neutralizing antibody response amongst people who already had pre-existing immunity to the disease in comparison to those who did not and an opinion was argued for if one dose could suffice in this sub-group thus bringing a larger population in the ambit of vaccination.[5-8] Such studies pave path for observing populations specific differences if any in eliciting a sufficient antibody response, while robust clinical trial data from manufacture is available.

This, as one of the first study from the country and regions utilizing Covishield vaccine aimed to understand the kinetics of antibody development in health-care workforce who stand as one of the most vulnerable in our fight against this pandemic. A large percentage of the health-care workforce had already been infected with SARS-CoV-2 and had developed antibodies against the virus. Thus, we also analyzed if being sero-positive leads to measurable differences in antibody levels and neutralizing antibody response compared to antibody naïve individuals after the administration of the first dose of vaccine.

The present study was carried at a tertiary level healthcare chain in Delhi, India where Covishield was administered to all personnel. Covishield is a replication deficient viral vector vaccine carrying SARS-CoV-2 Spike (S) glycoprotein to generate an antibody response. It had to be given in two doses spread 4-6 weeks apart to attain immunogenic levels, though it was observed through observational studies as mentioned in factsheet that the response is attainable even when the two doses are given 12 weeks apart rather being more effective at 12 weeks interval.[9 10]

Materials and Methodology

The study was approved by the ethics committees of Max Group of Hospitals, New Delhi and CSIR-IGIB, New Delhi. The subjects enrolled under a voluntary enrolment process after an informed consent were health care workers (HCW) at the Max Hospital Group who were to receive the Covishield vaccine to monitor their antibody response at days 0 before their first dose followed by sampling at day 7, 14, 28 and 45 with second dose on day 28. Herein, we analysed data of 307 subjects who had provided their samples on the day of receiving the first dose and on the 28th day i.e., the day they receive their second dose as per standard protocol. Of these 307 subjects, 166, 144 and 294 gave their samples at 7 (+/-3),14(+/-3), 28 (+/-3) days, respectively before receiving their second dose. 157 subjects' had given their blood samples at 45 (+/-3) days. Out of these 157 individuals; 20 did not receive their second dose of vaccine till 45 days of the first dose.

We also included the data of 33 subjects who were RT PCR positive for SARS-CoV-2 infection. These samples were collected as a part of another study. Samples were withdrawn at different time intervals from the day their RT-PCR test was positive. Median antibody levels were obtained for these subjects at Day 14-Day 28 (8 Subjects) and Day 29-Day 46 (12 subjects) and compared to antibody response with baseline antibody naïve subjects who didn't received their second dose of vaccination

Blood samples (6 ml) were collected in EDTA vials from each participant and antibodies to SARS-CoV-2 directed against the spike protein (S-antigen) were assayed using Elecsys Anti-SARS-CoV-2 S quantitative antibody detection kit (Roche Diagnostics) according to the manufacturer's protocol. Antibody levels >0.8 U/ml were sero-positive. The range of the kit is from 0.4 U/ml to 250 U/ml. For samples with values of >250 U/ml appropriate dilutions were made. Samples on Day 28 and Day 45 were further tested for neutralizing antibody (NAB) response directed against the spike protein using GENScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit (Genscript, USA), according to the manufacturer's protocol.[11]

Non-Parametric Mann-Whitney test was utilized to assess two groups i.e., those that had pre-existing antibodies and those who did not for time specific significant differences if any after assessment of data distribution. Chi square test with yates correction was performed for test proportion with cut-off of greater than 50 percent neutralizing antibody response on day 28 and day 45 after administration of second dose to assess difference if any. Statistical analysis was carried out with visualization in MS-Excel 2016 and OriginPro V2021.

Role of the funding source

The sponsor of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results and Discussion

This study was done in 307 heath care workers. Of these 307 subjects, 129 (42%) had already developed antibodies to SARS-CoV-2. These 307 subjects were assigned to two groups -seropositive (SP) and seronegative (SN), based on their serology status at baseline. We found that the antibody response at 7 days in the SP group was significantly higher than in the SN group ($p<0.0001$); rather, greater than ninety percent of individuals in the SN group did not develop any measurable response at day 7 (Figure 1A). This was corroborated at day 14 when individual in the SN group started developing antibodies, though the difference was still significant amongst the two groups ($p<0.0001$). On day 28, before the second dose of vaccination, most of the individuals amongst sero-negative group had measurable antibody response. About 2% of the individuals did not develop any measurable antibodies even after 28 days of the first dose.

In 137 individuals (50 SP and 87 SN) who got the second dose at 28 $\pm$ 3 days and provided their sample at day 45$\pm$ 3 days, the antibody levels remained significantly different between the two groups ($p<0.0001$). Interestingly, in the SP group, there was no further increase in the antibody levels after administration of the second dose (Figure 1B). However, in the SN group, the antibody levels kept rising after second dose but had not reached levels of baseline sero-positive group (Figure 1B).



Figure 1: Log Antibody titres in U/ml for Sero-Positive and Sero-Negative Subjects at Baseline (BL). A) Levels at Day 0, 7,14 and 28 after 1st Dose on Day 0. B) Levels at Day 28 and 45 in those who received and those who did not receive the second dose. Data of subjects with natural infection is also presented for comparison.

We also checked the neutralizing antibodies in these individuals and found that the median levels had reached 98% in the SP group after the first dose itself and remained stable even after the second dose. In the SN group, the median level of the neutralizing antibody was 45% after the first dose which increased to 82% after second dose. The difference amongst two groups for number of subjects who had greater than 50 percent neutralization capacity, which was significant on chi-square

test at day 28 after 1st dose ($p<0.0001$), became non-significant after second dose with NAb response (Figure 2).

Data of 20 subjects (11 SN, 9 SP), who had opted to delay the second dose of vaccination till 45th day of receiving the first dose, was analysed separately for both antibody levels and neutralizing antibody response. Antibody levels amongst baseline antibody naïve individuals (11 subjects) continue to rise even without the second dose of vaccine (median increase of 2.7 folds), albeit the median levels were lower than that observed with subjects who received the second dose of vaccine (Figure 1B). However, the neutralization antibody response did not increase in these naïve individuals (Figure 2), while it increased significantly in the group who had received the second dose of vaccine. For baseline sero-positive subjects (9 subjects), the antibody levels did not change at day 45 and were like subjects who had received second dose of vaccine (Figure 1B). Also, the neutralizing antibody response had already saturated in these subjects at day 28 and not receiving the second dose did not altered these levels (Figure 2).

We also determined the antibody levels (at single time point) for 20 subjects whose samples had been collected at different days following natural infection to SARS-CoV-2. It was observed that the median antibody levels were two-fold higher in samples collected between 28-45 days compared to 14-28 days after being RT-PCR positive. This indicates that the natural course follows a pattern similar to subjects who have only received a single dose of vaccine, and did not have pre-existing immunity to infection (Figure 1B). For these subjects neutralizing antibody response was observed at 74 percent on day 28 and 90 percent on day 45 (Figure 2), thus reflecting increase in neutralization capacity in natural course of infection which was not observed when subjects didn't take the second dose.



Figure 2: Neutralizing Antibody response comparison (%) for Sero-Positive (SP) and Sero-Negative (SN) subjects on day 28 and day 45 based on whether they took their second dose of vaccine or not at day 28 followed by response in persons who had natural course of infection.

When the neutralizing antibody response was analyzed against log antibody levels, it was observed that for most of baseline sero-positive group, neutralization antibody response had already peaked and saturated with 1st dose itself (Figure 3A). While, for baseline antibody naïve individuals, most of the subjects had achieved greater than 50 percent neutralization only after the second dose (Figure 3B). To achieve an effective neutralization capacity of greater than 50 percent; Sero-negative subjects on baseline were observed to be in requirement of having a minimum antibody level of 1.75 in log units which was achieved after second dose by most of the subjects (77/85) but not after the first dose (55/165).



Figure 3: Log Antibody levels (x-axis) and Neutralizing Antibody Levels (y-axis). A) For both Sero-Positive (SP) and Sero-Negative (SN) subjects at baseline on Day 28. B) For both Sero-Positive (SP) and Sero-Negative (SN) subjects at baseline on Day 45.

At Day 28, six subjects had not developed any antibody response after 1st dose of vaccine. Of these, 1 subject did not give sample at day 45 and 1 did not receive the second dose but gave the sample at day 49, although his/her antibody levels were detected nearly at the minimal threshold at day 49. Of the 4 individuals who received the second dose, three didn't develop any antibody response even at day 45 and remained sero-negative and 1 turned seropositive developing both antibody and neutralizing antibody response.

When post vaccination symptomatology was assessed, 206 subjects had given details on symptoms experienced on day 7 or day 14 of sampling for symptoms experienced in the first week following the first dose. 130 Individuals gave symptomatology data after second dose on 45th day sample collection. There was no difference observed in number of subjects reporting symptoms amongst antibody

positive and naïve individuals on Day 0, albeit percentage of subjects reduced to nearly half who reported any symptoms after second dose.

A limitation of this study is the small number of subjects who did not receive the second dose of vaccine by 45 days, and those being followed for natural course of infection. Further there is no group with delayed second dose to verify whether longer spacing between the vaccine shots has any benefit in terms of antibody response. Oxford/AstraZeneca vaccine which is being produced as Covishield in India had acceptable, rather a better response when two doses are given 12 weeks apart.[9 10] Inhibition of the viral vector due to vector-targeted immune response with the first dose has been considered as a reason. This is not an issue with mRNA vaccines. However, the overall considerations are similar. A single dose of Pfizer and Moderna vaccine has been found to be effective in people with pre-existing immunity.[5 6 8] However, at a general population level, the vaccine efficiency improved substantially after second dose[12] and a single dose was not good enough from a large scale study from Israel.[13] There are also important concerns regarding delaying the second dose, from the point of view of a longer vulnerable period, which should be taken seriously in context of current vaccination program and pandemic spread.[14] The vaccination dosing in India had been deliberately kept short to elicit effective immune response amongst vulnerable members.

Optimal timing of second dose can be thought of as a maximal duration of protection with minimal period of vulnerability. Our data shows that by 4 weeks after a single dose, there is 98% seroconversion. However, the second dose does importantly boost the antibody response and importantly provides significantly higher neutralization activity levels that may be clinically important in the presence of variants that may reduce neutralizing efficiency. Thus, we agree with concerns regarding delaying the dosing, while recognizing that answers must be context specific and cannot be universal. [15] Our data confirms an excellent response amongst individuals with pre-existing immunity which was corroborated with this study. Thus with the exception of subjects who are seropositive at baseline, the burden of proof for delaying the second dose during a pandemic is high. In absence of such information being routinely collected, vaccinating with two doses spaced 4 to 8 weeks apart, as per existing Indian guidelines, may preferred during rapid disease transmission in the community.

Conclusion

This work aimed to study pre-existing antibody status and antibody kinetics upon vaccination in healthcare workers being given two doses of Covishield. Our data shows that by 4 weeks after a single dose, there is 98% seroconversion, with subjects who were already seropositive at baseline reaching maximal response. However, in initially seronegative individuals, the second dose at 28 days importantly boosted the antibody response and neutralization effectiveness. This boost may be clinically important in the presence of variants that may reduce neutralizing efficiency and a 4-to-8-week gap, as practiced in India, seems appropriate.

Funding

Council of Scientific and Industrial Research, India

Conflict of Interest

Authors declare no competing interests

Acknowledgment

SSG would like to acknowledge CSIR grant for this work. SSG would like to acknowledge Manish Chowdhary, Yasmeen Khan and Preeti Subramani for sample analysis. SJ, SSG and DD would like to acknowledge all participants of the study.

References

1. Covid-19: Indian health officials defend approval of vaccine. *BMJ* 2021;372:n52. doi: 10.1136/bmj.n52
2. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet* 2020;396(10249):467-78. doi: 10.1016/S0140-6736(20)31604-4
3. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *The Lancet* 2020;396(10267):1979-93. doi: 10.1016/S0140-6736(20)32466-1
4. Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. *The Lancet Infectious Diseases* doi: 10.1016/S1473-3099(20)30942-7
5. Saadat S, Rikhtegaran Tehrani Z, Logue J, et al. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. *JAMA* 2021;325(14):1467-69. doi: 10.1001/jama.2021.3341
6. Krammer F, Srivastava K, Alshammary H, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *New England Journal of Medicine* 2021;384(14):1372-74. doi: 10.1056/NEJMc2101667
7. Wise J. Covid-19: People who have had infection might only need one dose of mRNA vaccine. *BMJ* 2021;372:n308. doi: 10.1136/bmj.n308
8. Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. *Nature Medicine* 2021 doi: 10.1038/s41591-021-01325-6
9. Wise J. Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval. *BMJ* 2021;372:n326. doi: 10.1136/bmj.n326
10. Voysey M CS, Madhi S, et al. . Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1nCoV-19 (AZD1222) vaccine. Available at SSRN: https://ssrn.com/abstract=3777268. 2021
11. Naushin S, Sardana V, Ujjainiya R, et al. Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV-2. *medRxiv* 2021:2021.01.12.21249713. doi: 10.1101/2021.01.12.21249713
12. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine* 2020;383(27):2603-15. doi: 10.1056/NEJMoa2034577
13. Mahase E. Covid-19: Reports from Israel suggest one dose of Pfizer vaccine could be less effective than expected. *BMJ* 2021;372:n217. doi: 10.1136/bmj.n217
14. Livingston EH. Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines. *JAMA* 2021 doi: 10.1001/jama.2021.1375

15. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *The Lancet* 2021 doi: https://doi.org/10.1016/S0140-6736(21)00432-3